Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients

NCT02386007 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute and Chronic Gastric Inflammation Patients

Interventions

DRUG: DW-3101_150mg
DRUG: DW-3101_300mg
DRUG: DW-3101_600mg
DRUG: Placebo

Sponsor

Daewon Pharmaceutical Co., Ltd.